Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Age, Lymph Node Positivity Link in Thyroid Cancer

October 16, 2018
By Naveed Saleh, MD, MS
Article

A new study in Cancer Management and Research found a correlation between the age of patients with papillary thyroid cancer and lymph node positivity.

Younger patients with papillary thyroid cancer (PTC) are more likely to exhibit lymph node positivity (LN+), a finding that could be useful to surgeons, according to a new study published in Cancer Management and Research.

“The correlation between LN+ and [the] patient’s age at diagnosis in PTC is still inconclusive,” wrote lead study author Jing Wang, of the Department of Head, Neck, and Breast Surgery at The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, China, and colleagues. “While several studies claimed that young age at diagnosis could be an independent predictor of LN+, one study showed that older PTC patients were more likely to exhibit higher LN+ rates, and another study did not find a correlation between age and LN+.”

Due to better screening and diagnostic testing, thyroid cancer is one of the most frequent cancers in the United States, and a substantial number of patients are young. Despite a 5-year survival rate of 98%, recurrence occurs in between 5% and 21% of cases.

Several studies have reported that the number of positive lymph nodes (PLNs) increases the risk of PTC recurrence. Additionally, research has found that the patient’s age at diagnosis impacted LN+ status in rectal cancer, breast cancer, and melanoma.

Using the high-powered SEER Incidence Database, Wang and colleagues set out to determine whether a younger age was correlated with elevated LN+ rates in patients with PTC. After assessing data for 46,077 PTC patients of various age groups, they found that, at each T stage, LN+ status was negatively correlated with age at diagnosis based on a multivariate logistic regression (P < .001) that accounted for sex, age, and surgery types. Patients aged 30 years or younger (18.2% of the sample) had the highest lymph node ratio (LNR) when compared with other age groups.

The team also discovered that younger age was correlated with a higher PLN and LNR when compared with older PTC patients at the equivalent T stage.

“Although the presence or absence of cervical LN+ does not affect mortality in younger PTC patients, locoregional LN recurrence would inevitably result in reoperation,” the authors wrote. “Indeed, the rate of injuring the recurrent nerve, parathyroid glands, or their circulation during reoperation is much higher than initial surgery.”

The researchers added that the higher risk associated with reoperations may impact quality of life, thus making age an important factor in surgical decision-making.

“Based on these data, I may consider a prophylactic central neck dissection in a younger patient with other features that put me ‘on the fence’ for considering this approach, but I would not use this information to start universally recommending this approach in our younger patients,” Bryan R. Haugen, MD, a professor of medicine and pathology at the University of Colorado Boulder, told Cancer Network.  “This should alert our community to try [to] design prospective studies to better answer these questions.”

Clinicians should bear in mind that use of the SEER database limited the clinical significance of the current study, noted Ryan K. Orosco, MD, a head and neck surgeon and an assistant professor of surgery at the University of California San Diego.

“The SEER database does not contain information about cancer recurrence, which is the critical outcome in the thyroid cancer population,” Orosco said during an interview with Cancer Network. “Although provocative, the data from the study do not tell us the downstream clinical significance of having a higher risk of positive lymph nodes at the time of thyroid surgery.”

Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content
Advertisement

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

Roman Fabbricatore
February 9th 2025
Article

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.


Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Related Content
Advertisement

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

Roman Fabbricatore
February 9th 2025
Article

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.


OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.


Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

Tim Cortese
December 1st 2024
Article

For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.


Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.


While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

Roman Fabbricatore
October 16th 2024
Article

While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.


Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.